Catalyst Event
WuXi XDC Cayman Inc (2268) · Earnings Release
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/23/2026, 12:00:00 AM
Announced full-year 2025 results on March 23, 2026, with revenue increasing 46.7% YoY to RMB 5.944 billion and adjusted net profit rising 69.9% YoY to RMB 1.559 billion.
Korean Translation
2026년 3월 23일 2025년 연간 실적 발표, 매출은 전년 동기 대비 46.7% 증가한 59억 4,400만 위안, 조정 순이익은 69.9% 증가한 15억 5,900만 위안을 기록함.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM